ArticlePrecision clinical medicine2026
KARAP deficiency alleviates intestinal mucosal barrier dysfunction by regulating mitochondrial homeostasis in macrophages.
Article in Precision clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Killer cell activating receptor-associated protein (KARAP) has been implicated in the progression of various inflammatory and immune-mediated diseases, including ulcerative colitis (UC). Although macrophages play a pivotal role in UC pathogenesis, how KARAP regulates macrophage immune responses remains poorly understood. Methods: In this study, KARAP expression was assessed in peripheral blood mononuclear cells (PBMCs) and colonic tissues from patients with UC using quantitative real-time PCR and immunofluorescence. Dextran sulfate sodium (DSS)-induced colitis was established in KARAP knockout (KARAP⁻ Results: KARAP expression was increased in PBMCs from patients with UC and was particularly high in macrophages. In the DSS-induced colitis model, KARAP deficiency improved intestinal barrier integrity by preserving macrophage mitochondrial homeostasis. KARAP blockade also increased interleukin (IL)-10 expression, thereby further preserving intestinal mucosal barrier integrity. Mechanistically, increased IL-10 expression depended on enhanced mechanistic target of rapamycin (mTOR)/mitophagy-mediated mitochondrial homeostasis in KARAP⁻ Conclusions: Our findings indicate that KARAP contributes to the regulation of intestinal mucosal barrier integrity by modulating macrophage mitochondrial homeostasis and IL-10 expression. Overall, these results offer new insight into the potential of KARAP as a new target for UC treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.